–
Neumora Therapeutics, Inc.
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25
(positive)
Change from FY22 to FY25
millions USD
FY21:
FY22:
−115
FY23:
−163
FY24:
−183
FY25:
−206
Change from FY21 to FY25
millions USD
FY21:
−0.82
FY22:
−168
FY23:
64.4
FY24:
−70.6
FY25:
169
Change from FY22 to FY25
millions USD
FY21:
–
FY22:
116
FY23:
232
FY24:
21.6
FY25:
77.1
millions USD
FY21:
–
FY22:
−167
FY23:
133
FY24:
−232
FY25:
39.2
(positive)
Change from FY21 to FY23
millions USD
FY21:
−76.2
FY22:
−115
FY23:
−163
FY24:
–
FY25:
–
All amounts in millions USD FY21: figures supplemented from Twelve Data because the SEC filings do not reach back this far.